Volociximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | α5β1 integrin |
| Identifiers | |
| CAS Number |
558480-40-3  |
| ATC code | none |
| ChemSpider | none |
| UNII |
496K5Z02NW  |
| KEGG |
D06319 |
| Chemical data | |
| Formula | C6434H9942N1706O2040S52 |
| Molar mass | 145.5 kg/mol |
| (what is this?) (verify) | |
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]
It is thought to reduce metastases. Early results show potential in renal cell cancers.
References
- ↑ Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer chemotherapy and pharmacology 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731.
External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, April 14, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.